ABL Bio Inc. (KOSDAQ:298380)

Market Cap	13.53T
Revenue (ttm)	88.44B +173.6%
Net Income	-28.65B
EPS	-575.68
Shares Out	55.13M
PE Ratio	n/a
Forward PE	1,679.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,893,184
Average Volume	1,432,245
Open	244,500
Previous Close	241,500
Day's Range	235,500 - 257,500
52-Week Range	31,300 - 257,500
Beta	0.51
RSI	68.66
Earnings Date	Feb 6, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatm...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2016
• Employees: 102
• Stock Exchange: KOSDAQ
• Ticker Symbol: 298380

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.